NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.25% | -3.25% | -13.20% | -16.87% | -3.83% |
| Depreciation & Amortization | 4,266.67% | 2,166.67% | 1,250.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.63% | -11.62% | -24.44% | -39.24% | -27.73% |
| Operating Income | 1.51% | 17.84% | 25.63% | 39.24% | 27.73% |
| Income Before Tax | -1.79% | -13.92% | -86.76% | -36.16% | 5.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.79% | -13.92% | -86.76% | -36.16% | 5.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.79% | -13.92% | -86.76% | -36.16% | 5.96% |
| EBIT | 1.51% | 17.84% | 25.63% | 39.24% | 27.73% |
| EBITDA | 2.14% | 18.09% | 25.67% | 39.25% | 27.74% |
| EPS Basic | 35.36% | 34.01% | -6.81% | 20.27% | 38.37% |
| Normalized Basic EPS | 43.03% | 43.86% | 25.85% | 34.95% | 39.19% |
| EPS Diluted | 35.36% | 34.01% | -6.81% | 20.27% | 38.74% |
| Normalized Diluted EPS | 43.03% | 43.86% | 25.85% | 34.95% | 39.19% |
| Average Basic Shares Outstanding | 102.29% | 100.81% | 79.17% | 61.55% | 54.60% |
| Average Diluted Shares Outstanding | 102.29% | 100.81% | 79.17% | 61.55% | 54.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |